[The characteristics of @entity751 in XXXX with prevalent phases of @entity978 before treatment].

@entity1 @entity417 @entity69 @entity1307 @entity102 @entity751 @entity978 @entity68
The study was carried out to analyze peripheral blood covering 23 @entity1 with prevalent phases of @entity978 received no treatment previously. The clinical analysis of blood was implemented using hematologic analyzer Sysmex XE-2100. The content of ferritin, soluble receptors of @entity69 and @entity1307 was estimated using enzyme-linked immunosorbent assay. The free hemoglobin was estimated using hemoglobin cyanide method. The direct Coombs test, counting of leukogram and analysis of morphology of erythrocytes were applied to all @entity1 . The @entity417 is diagnosed in 19 @entity1 (83%). In 18 out of them the @entity751 corresponded to @entity417 and in one @entity1 asiderotic @entity417 was established. The rest of @entity1 had no @entity417 . The @entity417 of @entity102 characterized by microcytosis and hypochromia of erythrocytes, inadequate degree of @entity417 by production of @entity1307 and functional deficiency of @entity68 in most of the @entity1 . It should be emphasized that @entity417 of @entity102 commonly is normocyte normochrome @entity417 whereas in @entity1 with prevalent phases of Hodgkin Iymphoma the microcyte hypochrome @entity417 was detected before the treatment and it was followed by functional deficiency of @entity68 . In @entity1 without @entity751 microcytosis and hypochromia of erythrocytes were marked too. The techniques of laboratory diagnostic objectively reflecting @entity68 metabolism (evaluation of level of soluble receptors of @entity69 andferritin) and appropriate hormonal response to degree of @entity417 (production of @entity1307 ) are to be included into algorithm of treatment of @entity1 . The purpose is to timely detect type of @entity417 with the purpose of its appropriate correction prior to treatment onset.
